| payload |
{"created_at":"2026-04-10T17:21:18.772 {"created_at":"2026-04-10T17:21:18.772571+00:00","signal_type":"discovery_new_listings_delta","source":"discovery_ingestor","url":"https://www.nasdaq.com/articles/kymr-set-earn-milestone-payment-gild-secures-license-kt-200","value":{"fp":"fffae612a44a87bf","kind":"new_listings","published_at":"2026-04-10T16:04:00+00:00","source":"Nasdaq Stocks","summary":"Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.","tickers":[],"title":"KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200","url":"https://www.nasdaq.com/articles/kymr-set-earn-milestone-payment-gild-secures-license-kt-200"}}... |